PT  - JOURNAL ARTICLE
AU  - Grant R. Stenton
AU  - Osamu Nohara
AU  - René E. Déry
AU  - Harissios Vliagoftis
AU  - Mark Gilchrist
AU  - Ankur Johri
AU  - John L. Wallace
AU  - Morley D. Hollenberg
AU  - Redwan Moqbel
AU  - A. Dean Befus
TI  - Proteinase-Activated Receptor (PAR)-1 and -2 Agonists Induce Mediator Release from Mast Cells by Pathways Distinct from PAR-1 and PAR-2
AID  - 10.1124/jpet.302.2.466
DP  - 2002 Aug 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 466--474
VI  - 302
IP  - 2
4099  - http://jpet.aspetjournals.org/content/302/2/466.short
4100  - http://jpet.aspetjournals.org/content/302/2/466.full
SO  - J Pharmacol Exp Ther2002 Aug 01; 302
AB  - Because thrombin-induced inflammation is partially mast cell-dependent and involves proteinase-activated receptors (PARs), we hypothesized that mast cells express PAR and can be stimulated with PAR-activating peptides (PAR-AP). We demonstrated that rat peritoneal mast cells expressed PAR-1 and PAR-2 mRNA, and that PAR-2AP (tc-LIGRLO-NH2, 1 μM) induced 64.2 ± 4.4% specific β-hexosaminidase release from peritoneal mast cells, whereas another PAR-2AP (SLIGRL-NH2, 10 μM), trypsin (40 U/ml), and mast cell tryptase (1.5 μg/ml) did not. PAR-1AP (ApfFRChaCitY-NH2, 10 μM) (Cit) induced 11.7 ± 3.7% specific β-hexosaminidase release, whereas another PAR-1AP (TFLLR-NH2, 40 μM) and human thrombin (10 U/ml) did not. PAR-AP, tc-LIGRLO-NH2, and Cit increased the free intracellular Ca2+ concentration, whereas trypsin, tryptase, thrombin, and other PAR-APs did not. Desensitization of Ca2+ flux with different agonists suggests that although tc-LIGRLO-NH2, Cit, and compound 48/80 have similar mechanisms of action, tc-LIGRLO-NH2 also activates mast cells by a mechanism distinct from that of 48/80. Using benzalkonium chloride, which antagonizes the actions of 48/80 by competing for the same Gi protein, we determined that benzalkonium chloride suppressed tc-LIGRLO-NH2-mediated (0.1 μM) β-hexosaminidase release by 62%. Moreover, removal of sialic acid from peritoneal mast cells, using neuraminidase (2 U/ml), inhibited Cit- (10 μM, 52%) and tc-LIGRLO-NH2 (0.5 μM, 29%)-mediated β-hexosaminidase release. Thus, tc-LIGRLO-NH2 and Cit have at least partially similar mechanisms of action as 48/80. PAR-AP may therefore activate mast cells via multiple mechanisms that are distinct from those of classical PAR-1 and PAR-2. The responsiveness of mast cells to PAR-AP via a non-PAR-1/non-PAR-2 mechanism complicates the interpretation of in vivo studies using these peptides. The American Society for Pharmacology and Experimental Therapeutics